Study on outcomes of patients undergoing stem cell transplantation
Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study
This study looks at the experiences and outcomes of patients who have had or are about to have stem cell transplants to see how their treatment and health changes over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 3 sites (Shanghai, Shanghai Municipality and 2 other locations) |
| Trial ID | NCT06708130 on ClinicalTrials.gov |
What this trial studies
This observational study collects clinical data from patients who have undergone or are proposed to undergo allogeneic hematopoietic stem cell transplantation. It aims to evaluate the natural course of the disease and current treatment modalities by analyzing treatment regimens, duration, and healthcare expenditures. Patients will complete questionnaires regarding their demographics and disease history, while treatment decisions will be made by their physicians based on standard practices. The study will follow patients over time, even if they participate in other interventional trials.
Who should consider this trial
Good fit: Ideal candidates include patients who have visited a stem cell transplant center and are undergoing or have undergone hematopoietic stem cell transplantation since January 1, 2021.
Not a fit: Patients with serious concomitant diseases or those unable to adhere to study requirements due to addiction or safety concerns may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and efficiency of current treatment approaches for hematologic conditions.
How similar studies have performed: Other observational studies in hematopoietic stem cell transplantation have shown success in providing real-world data, making this approach both relevant and valuable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. At least one visit to a stem cell transplant center beginning January 1, 2021 2. Proposed to undergo or have undergone hematopoietic stem cell transplantation Exclusion Criteria: 1. Long-term follow-up information for patients not available for any reason (e.g., unavailable or with serious concomitant disease) according to investigator opinion 2. Due to alcohol and drug addiction thus affecting their ability to follow the requirements of the study 3. Presence of conditions that could jeopardize patient safety or affect their adherence to the protocol, according to the investigator's opinion
Where this trial is running
Shanghai, Shanghai Municipality and 2 other locations
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine — Shanghai, Shanghai Municipality, China (Recruiting)
- Shanghai Liquan Hospital — Shanghai, China (Not_yet_recruiting)
- Shanghai Zhaxin Hospital — Shanghai, China (Not_yet_recruiting)
Study contacts
- Study coordinator: Xiaoxia Hu
- Email: hu_xiaoxia@126.com
- Phone: (86) 13795437259
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.